PMDA's challenge to accelerate clinical development and review of new drugs in Japan
- PMID: 20856242
- DOI: 10.1038/clpt.2010.190
PMDA's challenge to accelerate clinical development and review of new drugs in Japan
Abstract
In recent years, Japan's Pharmaceuticals and Medical Devices Agency (PMDA) has conducted several projects to shorten drug development and review times in Japan to resolve the "drug lag." Key to achieving this goal is greater involvement by the PMDA in drug development through enhancement of scientific consultation and improvement of the review process by reinforcing the operational system, including hiring more reviewers. We discuss here the current projects of the PMDA as well as future challenges.
Comment on
-
Clinical development and review times for new drugs in Japan: associated factors.Clin Pharmacol Ther. 2010 Oct;88(4):487-91. doi: 10.1038/clpt.2010.108. Epub 2010 Aug 25. Clin Pharmacol Ther. 2010. PMID: 20739921
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
